Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows
AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space
You may also be interested in...
The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.
High-level executive changes at AstraZeneca continue pondering of where the British pharma turns next for growth – will it look to large-scale M&A again?
Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.